<DOC>
	<DOCNO>NCT01864876</DOCNO>
	<brief_summary>This protocol phase 1 , randomize , single-blinded study evaluate safety tolerability single 5 mcg dose GLA-SE administer intramuscularly GLA-AF administer subcutaneously . The second focus detail global immune response measure systemic cytokine , chemokines , global gene regulation . The third focus investigate effect GLA peripheral blood immune cell include monocyte dendritic cell . The result trial generate supportive human data use GLA adjuvant dendritic cell-targeted vaccine strategy .</brief_summary>
	<brief_title>The Effects GLA ( 5 mcg ) Human Volunteers</brief_title>
	<detailed_description />
	<criteria>1 . Healthy adult male female , assess medical history , physical exam , laboratory test ; 2 . Age least 18 year age day screen great 50 year time administration ; 3 . Willing comply requirement protocol available followup plan duration study ( screen plus 4 week ) ; 4 . Willing undergo HIV test counsel receive HIV test result ; 5 . If female child bear potential , must willing use two effective method contraception ( combined oral contraceptive pill ; injectable contraceptive ; diaphragm ; Intra Uterine Device ( IUD ) ; condom ; anatomical sterility self partner ) 6 week study drug administration . If sexually active male , must willing use two effective method contraception ( condom , anatomical sterility ) screen 6 week study drug administration ( ) advise get partner ( ) pregnant time . 1 . Positive hepatitis B surface antigen , positive hepatitis C antibody , active syphilis infection base clinical evaluation ; 2 . Confirmed HIV1 HIV2 infection ; 3 . Any clinically significant abnormality medical history physical examination include history immunodeficiency autoimmune disease ; 4 . Any use systemic corticosteroid immunosuppressive anticancer medication ; 5 . Any clinically significant acute chronic medical condition require care physician ( e.g. , diabetes , coronary artery disease , rheumatologic illness , malignancy , substance abuse ) opinion investigator would preclude participation ; 6 . Any laboratory value outside reference range CRP , exception nonclinically significant Grade I elevations liver function test ( AST , ALT , direct/total bilirubin ) , electrolytes ( Na , K , Cl , CO2 ) , CBC , urinalysis determine Principal Investigator designee . 7 . Within 12 month prior enrollment , subject self report excessive daily alcohol use , frequent binge drinking chronic marijuana abuse ( define great 2 time week ) use illicit drug ; 8 . If female , pregnant , plan pregnancy trial period , lactate ; 9 . Receipt live attenuate vaccine within 30 day vaccine within 14 day prior study drug ; 10 . Prior receipt GLA another research study ; 11 . Participation another clinical study investigational product currently within past 16 week , expect participation study ; 12 . In opinion investigator , unlikely comply protocol due medical , social psychiatric reason ; 13 . Allergy egg 14 . A glomerular filtration rate le 60 mL/min/1.73 m2 calculate study team base laboratory creatinine value .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>